| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MDM2 |
| Uniprot No | Q00987-11 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-118aa |
| 氨基酸序列 | MHHHHHHGSMCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSV GAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSF SVKEHRKIYTMIYRNLVVVNQQESSDS |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于MDM2重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*In vivo activation of the p53 pathway by small-molecule antagonists of MDM2*
**作者**：Vassilev, L.T. 等
**摘要**：该研究报道了通过重组MDM2蛋白筛选出的小分子抑制剂(如Nutlin)，可特异性阻断MDM2与p53的相互作用，激活p53通路，抑制肿瘤生长，为癌症治疗提供新策略。
2. **文献名称**：*Structural basis for inhibition of the MDM2 oncoprotein by anticancer agents*
**作者**：Kussie, P.H. 等
**摘要**：通过X射线晶体学解析了重组MDM2蛋白与p53肽段及小分子抑制剂的复合物结构，揭示了MDM2-p53结合界面的关键位点，为药物设计提供结构基础。
3. **文献名称**：*MDM2 small-molecule antagonist triggers p53-dependent apoptosis in cancer cells*
**作者**：Tovar, C. 等
**摘要**：利用重组MDM2蛋白验证了一类新型小分子化合物的结合活性，证明其通过恢复p53功能诱导癌细胞凋亡，支持靶向MDM2的抗癌药物开发。
4. **文献名称**：*Structural-guided optimization of MDM2 inhibitors using recombinant protein assays*
**作者**：Wade, M. 等
**摘要**：基于重组MDM2蛋白的生化分析，结合结构生物学手段优化了抑制剂分子，显著提高了其对MDM2的选择性和抗肿瘤活性。
---
这些文献涵盖了MDM2重组蛋白在结构解析、药物筛选及机制研究中的关键应用，均为该领域的经典或高影响力研究。
MDM2 (Mouse Double Minute 2 Homolog) is an E3 ubiquitin ligase encoded by the *MDM2* gene in humans, playing a central role in regulating the tumor suppressor protein p53. Under normal conditions, MDM2 binds to p53. promoting its ubiquitination and subsequent proteasomal degradation, thereby maintaining low cellular levels of p53 and preventing uncontrolled cell cycle arrest or apoptosis. This negative feedback loop ensures balanced cell proliferation and stress response. However, dysregulation of MDM2. such as gene amplification or overexpression, is frequently observed in cancers, leading to excessive inactivation of p53 and tumor progression.
Recombinant MDM2 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional MDM2 for research and therapeutic applications. It typically retains critical domains, including the N-terminal p53-binding region, a central acidic domain, and a C-terminal RING finger domain essential for its E3 ligase activity. Researchers utilize recombinant MDM2 to study its interaction with p53. screen for small-molecule inhibitors (e.g., Nutlin-3) that disrupt MDM2-p53 binding, and explore cancer therapies aimed at restoring p53 function. Structural studies using recombinant MDM2 have also clarified mechanisms of oncogenicity and resistance, aiding drug design. Additionally, truncated or mutated variants help dissect functional domains or mimic pathological conditions. As a key target in precision oncology, MDM2 remains pivotal in understanding cancer biology and developing targeted treatments.
×
